TITLE

New drugs and dosage forms

PUB. DATE
February 2011
SOURCE
American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p194
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the new kinds of drugs and dosage forms including Aliskiren, Moxifloxacin hydrochloride, and Testosterone gel.
ACCESSION #
57656990

 

Related Articles

  • Combination Pill Approved for High Blood Pressure.  // Journal of Gerontological Nursing;Nov2009, Vol. 35 Issue 11, p7 

    The article reports on the move of the U.S. Food and Drug Administration to approve the combination drug Valturna for treatment of high blood pressure. The drug is a combination of valsartan, the active ingredient in the blood pressure medication Diovan, and aliskiren, the active ingredient in...

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788 

    The article offers information on the use of new drugs for specific treatments including dexamethasone intravitreal implant for noninfectious ocular inflammation, combination of drospirenone, ethinyl estradiol, and levomefolate calcium tablets and levomefolate calcium tablets for pre-menstrual...

  • Natazia for contraception.  // Monthly Prescribing Reference;Jun2010, Vol. 26 Issue 6, pA.17 

    The article reports that the Food and Drug Administration (FDA) approved the use of estradiol valerate/dienogest tablets Natazia from Bayer Healthcare AG as oral contraceptive in the U.S.

  • Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials*This paper is based on a Cochrane review published in the Cochrane Library, 2005 issue 3, (see www.thecochranelibrary.com for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review. A. Edelman; M.F. Gallo; M.D. Nichols; J.T. Jensen; K.F. Schulz; D.A. Grimes // Human Reproduction;Mar2006, Vol. 21 Issue 3, p573 

    BACKGROUND: With the recent US Food and Drug Administration approval of a combination oral contraceptive that causes a withdrawal bleed every 3 months instead of monthly, avoidance of menstruation through extended or continuous administration (>28 days of active pills) of combined oral...

  • Niacin/simvastatin Extended-Release Tablets (Simcor). Elliott, William T.; Chan, James // Internal Medicine Alert;3/15/2008, Vol. 30 Issue 5, p37 

    The article discusses the approval of Food and Drug Administration (FDA) of extended release niacin plus simvastatin as a combination product for the treatment of hyperlipidemian, which also include its dosage, potential advantages and disadvantages and some clinical implications.

  • Doxylamine Succinate and Pyridoxine HCl Delayed-Release Tablets (Diclegis®). Elliott, William T.; Chan, James // Internal Medicine Alert;5/15/2013, Vol. 35 Issue 9, p69 

    The article focuses on the efficacy and safety of doxylamine/pyridoxine including its indications, dosage, and clinical implications.

  • FDA actions. Elliott, William T. // Primary Care Reports;Jun2013 Pharmacology Watch, p2 

    The article focuses on the recent actions taken by the Food and Drug Administration (FDA). It is mentioned that the FDA has approved the relabelling of newer tamper-proof oxycodone (OxyContin) drugs to reduce its abuse. It states that a fixed combination of doxylamine succinate and pyridoxine...

  • FDA actions.  // Internal Medicine Alert;6/15/2013 Pharmacology Watch, p2 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for a once-daily combination inhaler for the treatment of chronic obstructive pulmonary disease (COPD) which combines the long-acting beta-agonist (LABA) vilanterol with the steroid fluticasone furoate.

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Jul2013 Pharmacology watch, p2 

    The article reports on the approval made by the U.S. Food and Drug Administration (FDA) of a once-daily inhaler for treatment of chronic obstructive pulmonary disease (COPD) and a cholesterol combination drug, combining ezetimibe and atorvastatin.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics